Compare CIF & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CIF | AYTU |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.7M | 25.7M |
| IPO Year | N/A | 2015 |
| Metric | CIF | AYTU |
|---|---|---|
| Price | $1.62 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 49.6K | 44.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $1.52 | $0.95 |
| 52 Week High | $1.82 | $3.07 |
| Indicator | CIF | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 55.43 |
| Support Level | N/A | $2.14 |
| Resistance Level | $1.73 | $2.66 |
| Average True Range (ATR) | 0.02 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 40.93 | 62.50 |
Mfs Intermediate High Income Fund is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income, but it may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment-grade corporate bonds, government securities and other securities. The portfolio includes Midstream, Financial Institutions, Energy, Cable TV, and Utilities.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.